A fusion protein combining thymosin alpha-1 with B-lymphocyte stimulator (BLyS) was expressed in E. coli, potentially combining T-cell and B-cell immune enhancement in a single molecule for comprehensive immunotherapy.
Key findingThymosin alpha-1-cBLyS fusion protein expressed in E. coli combined T-cell immune enhancement (thymosin alpha-1) with B-cell stimulation (BLyS), creat
What the researchers found
Thymosin alpha-1-cBLyS fusion protein expressed in E. coli combined T-cell immune enhancement (thymosin alpha-1) with B-cell stimulation (BLyS), creating a dual-arm immunostimulatory molecule for potential comprehensive immunotherapy.
Why it matters
Relevant for thymosin-alpha-1, immune-function, peptide-design.
How the study worked
in-vitro study on thymosin-alpha-1, immune-function.
What this study cannot tell us
See abstract.
How to read the evidence
preliminary evidence.
When this study was published
Published in 2005.
The bigger picture
Advances peptide/biomarker research.
Questions still open
- Further research needed.
- Clinical translation to evaluate.
Common questions
What was studied?
What was found?
Read the original research
Construction and expression of a new fusion protein, thymosin alpha1-cBLyS, E. coli.
Biotechnology letters, 27(3), 143-8
Citation
Shen, Qiong; Tian, Ruiyang; Ma, Wenzhe; Yuan, Qinsheng; Gong, Yi. (2005). Construction and expression of a new fusion protein, thymosin alpha1-cBLyS, E. coli.. Biotechnology letters, 27(3), 143-8.